2,441 results on '"Vaginal cancer"'
Search Results
2. A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
- Published
- 2024
3. ASk Questions in GYnecologic Oncology (ASQ-GYO) (ASQ-GYO)
- Author
-
Ira Winer, Principle Investigator
- Published
- 2024
4. Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
- Published
- 2024
5. Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
- Author
-
Chongqing Bovax Biopharmaceutical Co., Ltd.
- Published
- 2024
6. Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
- Author
-
Chongqing Bovax Biopharmaceutical Co., Ltd.
- Published
- 2024
7. Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
- Published
- 2024
8. Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
- Published
- 2024
9. Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
- Author
-
Emma Barber, Assistant Professor
- Published
- 2024
10. Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer (TRIDENT)
- Published
- 2024
11. Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies (Reiki-Brachy)
- Published
- 2024
12. Application of PET/MRI in Gynecologic Malignancies
- Author
-
Ebrahimi, Sheida, Lundström, Elin, Batasin, Summer J, Hedlund, Elisabeth, Stålberg, Karin, Ehman, Eric C, Sheth, Vipul R, Iranpour, Negaur, Loubrie, Stephane, Schlein, Alexandra, and Rakow-Penner, Rebecca
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Bioengineering ,Women's Health ,Clinical Research ,Biomedical Imaging ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,4.1 Discovery and preclinical testing of markers and technologies ,PET/MRI ,gynecological malignancy ,cervical cancer ,endometrial cancer ,ovarian cancer ,vaginal cancer ,Oncology and carcinogenesis - Abstract
The diagnosis, treatment, and management of gynecologic malignancies benefit from both positron emission tomography/computed tomography (PET/CT) and MRI. PET/CT provides important information on the local extent of disease as well as diffuse metastatic involvement. MRI offers soft tissue delineation and loco-regional disease involvement. The combination of these two technologies is key in diagnosis, treatment planning, and evaluating treatment response in gynecological malignancies. This review aims to assess the performance of PET/MRI in gynecologic cancer patients and outlines the technical challenges and clinical advantages of PET/MR systems when specifically applied to gynecologic malignancies.
- Published
- 2024
13. NYSCF Scientific Discovery Biobank
- Published
- 2024
14. Integrated Cancer Repository for Cancer Research (iCaRe2)
- Published
- 2024
15. Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study (GynCAT)
- Author
-
Fondazione Umberto Veronesi and Pola Roberto, Professor
- Published
- 2024
16. GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
- Author
-
Merck Sharp & Dohme LLC
- Published
- 2024
17. Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation (MIFADORESOL)
- Published
- 2024
18. Trends in HPV‐associated cancer incidence in Texas medically underserved regions.
- Author
-
Hoang, Thao N., Berenson, Abbey B., Shan, Yong, Guo, Fangjian, Adekanmbi, Victor, Hsu, Christine, Yu, Xiaoying, and Kuo, Yong‐Fang
- Subjects
- *
MEDICALLY underserved areas , *HUMAN papillomavirus , *OROPHARYNGEAL cancer , *VAGINAL cancer , *CERVICAL cancer , *VULVAR cancer - Abstract
Background: While cervical cancer incidence rates (IR) in the United States have dropped in the last 20 years, non‐cervical human papillomavirus (HPV) associated cancers increased. Many people in Texas (TX) live in medically underserved areas and have higher risk of developing HPV‐associated cancers. Since previous studies of these regions focused on cervical cancer, we included other HPV‐associated cancers in our analysis of IR in East TX and the TX‐Mexico Border compared to other TX regions. Methods: Cancer data from 2006 to 2019 were obtained from the TX Cancer Registry. Cases of HPV‐associated cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers and corresponding patient‐level demographic data were included. We calculated IR per 100,000 and drew heat maps to visualize cancer IR by county. To control potential confounders, we added county‐level risk factors: rates for smoking, excessive drinking, obesity, STIs, primary care provider availability and dentist availability, from the County Health Rankings and Roadmaps program. We reported IRs by region and time and estimated unadjusted and adjusted risk ratio (RR) for association of each type of cancer and region. Lastly, we created adjusted models for each cancer by period to see time trends of regional differences. Results: Risk of anal, cervical, and oropharyngeal cancer was lower at parts of the Border than in the rest of TX in the adjusted model. We also observed increasing anal and oropharyngeal cancer risk and decreasing cervical and vaginal cancer risk over time. Conclusion: Patient sociodemographics, behavioral risk factors, and access to care may contribute to some observed differences in cancer IR across regions. This indicates that targeted prevention efforts towards these regions, especially in low socioeconomic status communities, may benefit future generations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Uncommon high distribution of HPV-16, HPV-54, and HPV-56 in female referred to a laboratory in Karaj, Iran: indications of a paradigm shift in HPV genotypes?
- Author
-
Letafati, Arash, Motlaghzadeh, Saeed, Ardekani, Omid Salahi, Memarpour, Bahar, Seyedi, Saba, Bahari, Mahshid, Farahani, Ali Vasheghani, Khoshravan, Amir, Sarrafzadeh, Sheida, Vasmehjani, Abas Ahmadi, Pournaseri, Maryam, Bahrami, Yegane, and Talebi, Fatemeh
- Subjects
- *
HUMAN papillomavirus , *SEXUALLY transmitted diseases , *ANAL cancer , *VAGINAL cancer , *VIRUS diseases - Abstract
Background: Human papillomavirus (HPV) is among the leading cause of sexually transmitted infections, particularly prevalent among sexually active individuals. While many HPV infections clear up over time, some may progress to various cancers such as anal cancer, cervical cancer and, vaginal cancer. This study examines the prevalence of different HPV genotypes, classified as high-risk (HR) and low-risk (LR), among females of various age groups who visited the laboratory in Karaj. Material and methods: Genital specimens were gathered from the individuals involved in the study and subjected to DNA extraction (DNA/RNA extraction AmpliSense, Moscow, Russia) followed by amplification using Real-Time PCR. HR- and LR-HPV genotypes were identified using the GenoFlow HPV Array test kit (GenoFlow; DiagCor Bioscience, Hong Kong) and homemade HPV genotyping kit. Demographic information such as age, was examined alongside statistical virological data. Results: Overall, 367 (17%) out of the 2109 (100%) female cases tested positive for HPV. Among these, 219 (46.2%) were classified as low-risk, 44 (9.3%) as potentially high-risk, and 211 (44.5%) as high-risk. The highest percentage of positive test results was detected in individuals under 30 years old (35%) and those aged 40–50 (18%). Individuals in the < 30 age group were primarily infected with HR genotypes. The most commonly identified genotypes overall were HPV-16 (11.7%), HPV-54 (10.3%), HPV-56 (8.4%), HPV-40 (8.1%). The lowest frequency was observed for HPV-70, HPV-71, HPV-82, and HPV-90, each recorded in only a single case. Conclusion: Our results highlight the notable occurrence of HPV among females who visited the laboratory in Karaj, especially in the < 30 age group. Identifying HPV-16 as the most prevalent genotype in our examination highlights the necessity of tailored interventions for specific age ranges. While HPV-16 is covered by vaccination programs, HPV-54 and HPV-56 are not, emphasizing the need for effective screening and preventive plans to manage the consequences of HPV-related diseases in future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. The risk of vaginal, vulvar and anal precancer and cancer according to high‐risk HPV status in cervical cytology samples.
- Author
-
Lindquist, Sofie, Frederiksen, Kirsten, Petersen, Lone Kjeld, and Kjær, Susanne K.
- Subjects
VULVAR cancer ,ANAL cancer ,HUMAN papillomavirus ,VAGINAL cancer ,PROPORTIONAL hazards models ,CERVICAL cancer - Abstract
High‐risk human papillomavirus (hrHPV) is the cause of virtually all cervical cancers, most vaginal and anal cancers, and some vulvar cancer cases. With HPV testing becoming the primary screening method for cervical cancer, understanding the link between cervical hrHPV infection and the risk of other anogenital cancers is crucial. We assessed the risk of vulvar, vaginal and anal cancer and precancer (VIN2+, VaIN2+ and AIN2+) in a prospective cohort study including 455,349 women who underwent cervical hrHPV testing in Denmark from 2005 to 2020. We employed Cox proportional hazard models, adjusting for age, calendar year and HPV vaccination status, and estimated hazard ratios (HRs) and 95% confidence intervals (CI). We used the Aalen Johansen estimator to calculate the absolute risks of VIN2+, VaIN2+ and AIN2+. In total, 15% of the women were hrHPV positive at baseline. A positive cervical hrHPV test was associated with increased incidence of vulvar, vaginal and anal squamous cell carcinoma (SCC). Five‐year risk estimates of VIN2+, VaIN2+ and AIN2+ among hrHPV‐positive women (0.45%, 0.14% and 0.12%) were higher than among hrHPV‐negative women (0.14%, 0.01% and 0.05%). Particularly high risk was observed among the hrHPV‐positive women of the oldest age, with a history of anogenital precancer and those not HPV vaccinated. In conclusion, our study confirms the association between cervical hrHPV infection and non‐cervical anogenital precancers and cancers. Currently, no established risk threshold or guidelines for follow‐up. As HPV testing becomes the primary method for cervical cancer screening, future data will help define high‐risk groups and acceptable risk thresholds. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Vulvar and Vaginal Cancers
- Author
-
Shylasree, T. S., Chopra, Supriya, Bansal, Richa, Bhattacharjee, Arnab, Bajpai, Jyoti, Badwe, Rajendra A., editor, Gupta, Sudeep, editor, Shrikhande, Shailesh V., editor, and Laskar, Siddhartha, editor
- Published
- 2024
- Full Text
- View/download PDF
22. Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
- Author
-
Chongqing Bovax Biopharmaceutical Co., Ltd.
- Published
- 2023
23. The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
- Published
- 2023
24. E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
- Author
-
Christian Hinrichs, Chief, Section of Cancer Immunotherapy
- Published
- 2023
25. E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
- Author
-
National Cancer Institute (NCI) and Christian Hinrichs, Co-director, Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence
- Published
- 2023
26. Dose-response relationship between volume base dose and tumor local control in definitive radiotherapy for vaginal cancer
- Author
-
Zhiqiang Wang, Xin Guo, and Hongfu Zhao
- Subjects
Vaginal cancer ,Brachytherapy ,Dose-response relationship ,Tumor control ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective This study aimed to establish the dose-response relationship between volume base dose and tumor local control for vaginal cancer, including primary vaginal cancer and recurrent gynecologic malignancies in the vagina. Materials and methods We identified studies that reported volume base dose and local control by searching the PubMed, the Web of Science, and the Cochrane Library Database through August 12, 2023. The regression analyses were performed using probit model between volume based dose versus clinical outcomes. Subgroup analyses were performed according to stratification: publication year, country, inclusion time of patients, patients with prior radiotherapy, age, primaries or recurrent, tumor size, concurrent chemoradiotherapy proportion, dose rate, image modality for planning, and interstitial proportion. Results A total of 879 patients with vaginal cancer were identified from 18 studies. Among them, 293 cases were primary vaginal cancer, 573 cases were recurrent cancer in the vagina, and 13 cases were unknown. The probit model showed a significant relationship between the HR-CTV (or CTV) D90 versus the 2-year and 3-year local control, P values were 0.013 and 0.014, respectively. The D90 corresponding to probabilities of 90% 2-year local control were 79.0 GyEQD2,10 (95% CI: 75.3–96.6 GyEQD2,10). Conclusions A significant dependence of 2-year or 3-year local control on HR-CTV (or CTV) D90 was found. Our research findings encourage further validation of the dose-response relationship of radical radiotherapy for vaginal cancer through protocol based multicenter clinical trials.
- Published
- 2024
- Full Text
- View/download PDF
27. An isolated vaginal metastasis from rectal cancer: a case report
- Author
-
Saida Sakhri, Ines Zemni, Mohamed Ali Ayadi, Ayoub Ghazouani, Nadia Boujelbene, and Tarek Ben Dhiab
- Subjects
Vaginal cancer ,Colorectal metastasis ,Oligometastatic disease ,Medicine - Abstract
Abstract Introduction Vaginal metastasis from colorectal cancer is a rare occurrence, typically associated with other metastatic lesions. Isolated metastasis is exceedingly uncommon, with only a few cases documented in the literature. Vaginal involvement in colorectal cancer primarily results from direct contiguous spread from the primary tumor. Case presentation We present the case of a 70-year-old African woman diagnosed with adenocarcinoma of the middle rectum. She underwent chemotherapy, radiotherapy, and subsequent anterior resection. After 2 months, an isolated metastasis of rectal cancer was identified in the lower third of the left vaginal wall, confirmed by biopsy. Colonoscopy ruled out colorectal recurrence. Thoraco-abdominal computed tomography scan showed no distant metastases. The patient underwent abdominoperineal resection, removing the lateral and posterior vaginal wall with free macroscopic margins and a definitive colostomy. The final histopathological analysis confirmed the diagnosis of moderately differentiated adenocarcinoma of the vagina, measuring 5 × 4.5 cm. The rectal wall was extrinsically invaded by the tumor down to the muscularis propria while respecting the rectal mucosa. Resection margins were negative. The patient was discharged 1 week postoperation with no complications. Adjuvant chemotherapy was indicated, and the patient is currently tolerating the treatment well. Conclusion Vaginal metastases from colorectal cancer are extremely rare. A vigilant gynecological examination is recommended during the follow-up of colorectal cancer patients. Diagnosis can be challenging, especially if the metastatic lesion is small and asymptomatic, even after standard radiological examination. Surgical resection followed by chemotherapy is a valid option for patients with early isolated metastases.
- Published
- 2024
- Full Text
- View/download PDF
28. Structured Literature Review to Identify Human Papillomavirus’s Natural History Parameters for Dynamic Population Models of Vaccine Impacts
- Author
-
Ibrahim Diakite, Bruno Martins, Kwame Owusu-Edusei, Cody Palmer, Oscar Patterson-Lomba, Andres Gomez-Lievano, Abigail Zion, Ryan Simpson, Vincent Daniels, and Elamin Elbasha
- Subjects
HPV ,Disease transmission models ,Cervical cancer ,Anal cancer ,Vaginal cancer ,Vulvar cancer ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Human papillomavirus (HPV) is a common sexually transmitted virus that can cause cervical cancer and other diseases. Dynamic transmission models (DTMs) have been developed to evaluate the health and economic impacts of HPV vaccination. These models typically include many parameters, such as natural history of the disease, transmission, demographic, behavioral, and screening. To ensure the accuracy of DTM projections, it is important to parameterize them with the best available evidence. This study aimed to identify and synthesize data needed to parametrize DTMs on the natural history of HPV infection and related diseases. Parameters describing data of interest were grouped by their anatomical location (genital warts, recurrent respiratory papillomatosis, and cervical, anal, vaginal, vulvar, head and neck, and penile cancers), and natural history (progression, regression, death, cure, recurrence, detection), and were identified through a systematic literature review (SLR) and complementary targeted literature reviews (TLRs). The extracted data were then synthesized by pooling parameter values across publications, and summarized using the range of values across studies reporting each parameter and the median value from the most relevant study. Data were extracted and synthesized from 223 studies identified in the SLR and TLRs. Parameters frequently reported pertained to cervical cancer outcomes, while data for other anatomical locations were less available. The synthesis of the data provides a large volume of parameter values to inform HPV DTMs, such as annual progression rates from cervical intraepithelial neoplasia (CIN) 1 to CIN 2+ (median of highest quality estimate 0.0836), CIN 2 to CIN 3+ (0.0418), carcinoma in situ (CIS) 2 to local cancer+ (0.0396), and regional to distant cancer (0.0474). Our findings suggest that while there is a large body of evidence on cervical cancer, parameter values featured substantial heterogeneity across studies, and further studies are needed to better parametrize the non-cervical components of HPV DTMs.
- Published
- 2024
- Full Text
- View/download PDF
29. Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature
- Author
-
Maria Giuseppa Vitale, Cecilia Nasso, Beatrice Riccò, Alessandro Bocconi, Chiara Chiavelli, Cinzia Baldessari, Stefania Pipitone, Francesca Bacchelli, Laura Botticelli, Massimo Dominici, and Roberto Sabbatini
- Subjects
vaginal cancer ,vulval cancer ,pembrolizumab ,immunotherapy ,case report ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, and vaginal carcinomas notoriously develop resistance to treatment, and consequently, their prognosis is still poor. Case Presentation: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy. Conclusion: Pembrolizumab might represent a promising option for the management of vaginal and vulvar cancer, but data to support its use in this setting are still lacking. This case highlights the need for further investigation and trial designs for this rare disease.
- Published
- 2024
- Full Text
- View/download PDF
30. Incidence distributions, risk factors and trends of vaginal cancer: A global population‐based study.
- Author
-
Huang, Junjie, Chan, Sze Chai, Pang, Wing Sze, Mak, Fung Yu, Fung, Yat Ching, Lok, Veeleah, Zhang, Lin, Lin, Xu, Lucero‐Prisno, Don Eliseo III, Xu, Wanghong, Zheng, Zhi‐Jie, Elcarte, Edmar, Withers, Mellissa, and Wong, Martin C. S.
- Subjects
- *
VAGINAL cancer , *GENITAL warts , *HUMAN papillomavirus , *UNSAFE sex , *HIV , *DISEASE risk factors - Abstract
Objective Design Setting Population Methods Main Outcome Measures Results Conclusions This study aimed to investigate the incidence, risk factors and trends for vaginal cancer.Retrospective observational design.Data were collected from multiple sources, including the Global Cancer Observatory, Cancer Incidence in Five Continents Plus, Global Burden of Disease, World Bank and the United Nations.Individuals diagnosed with vaginal cancer.The study collected data on vaginal cancer from the specified sources. The age‐standardised rate (ASR) of vaginal cancer was calculated for different regions and age groups. Multivariable and univariable linear regression analyses were performed to examine the associations between risk factors and the incidence of vaginal cancer. Trend analysis was conducted using joinpoint regression analysis, and the average annual percentage change (AAPC) was calculated to quantify the temporal trend.The main outcome measures of the study were the incidence of vaginal cancer, risk factors associated with the disease and the trend of its incidence over time.There were 17 908 newly reported cases of vaginal cancer (ASR = 0.36, 95% CI 0.30–0.44) in 2020, with the highest ASRs reported in South–Central Asia and Southern Africa. Risk factors associated with a higher incidence of vaginal cancer included a higher prevalence of unsafe sex and human immunodeficiency virus (HIV) infection. The temporal trend showed an overall rising incidence globally, with Iceland (AAPC = 29.56, 95% CI 12.12–49.71), Chile (AAPC = 22.83, 95% CI 13.20–33.27), Bahrain (AAPC = 22.05, 95% CI 10.83–34.40) and the UK (AAPC = 1.40, 95% CI 0.41–2.39) demonstrating the most significant rising trends.The significant regional disparities and risk factors associated with vaginal cancer underscore the necessity for targeted interventions and education, particularly in regions with a lower human development index (HDI) and a higher prevalence of human papillomavirus (HPV) infection. The increasing incidence trend emphasises the need for enhanced HPV vaccination rates to prevent the development of vaginal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Vaginal microbiota and gynecological cancers: a complex and evolving relationship.
- Author
-
Javadi, Kasra, Ferdosi-Shahandashti, Elaheh, Rajabnia, Mehdi, and Khaledi, Mansoor
- Subjects
- *
VAGINA , *OVARIAN tumors , *HUMAN microbiota , *VULVAR tumors , *EVALUATION of medical care , *FEMALE reproductive organ tumors , *ENDOMETRIAL tumors , *QUALITY of life ,CERVIX uteri tumors ,VAGINAL tumors - Abstract
The vagina hosts a community of microorganisms known as the vaginal microbiota. This community is relatively stable and straightforward, with Lactobacillus species being the most dominant members. The vaginal microbiota has various functions that are essential for maintaining human health and balance. For example, it can metabolise dietary nutrients, produce growth factors, communicate with other bacteria, modulate the immune system, and prevent the invasion of harmful pathogens. When the vaginal microbiota is disrupted, it can lead to diseases and infections. The observed disturbance is distinguished by a reduction in the prevalence of Lactobacillus and a concurrent rise in the number of other bacterial species that exhibit a higher tolerance to low oxygen levels. Gynecologic cancers are a group of cancers that affect the female reproductive organs and tissues, such as the ovaries, uterus, cervix, vagina, vulva, and endometrium. These cancers are a major global health problem for women. Understanding the complex interactions between the host and the vaginal microorganisms may provide new insights into the prevention and treatment of gynecologic cancers. This could improve the quality of life and health outcomes for women. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Dose-response relationship between volume base dose and tumor local control in definitive radiotherapy for vaginal cancer.
- Author
-
Wang, Zhiqiang, Guo, Xin, and Zhao, Hongfu
- Subjects
- *
VAGINAL cancer , *GYNECOLOGIC cancer , *CANCER radiotherapy , *CANCER patients , *TUMORS , *DATABASES - Abstract
Objective: This study aimed to establish the dose-response relationship between volume base dose and tumor local control for vaginal cancer, including primary vaginal cancer and recurrent gynecologic malignancies in the vagina. Materials and methods: We identified studies that reported volume base dose and local control by searching the PubMed, the Web of Science, and the Cochrane Library Database through August 12, 2023. The regression analyses were performed using probit model between volume based dose versus clinical outcomes. Subgroup analyses were performed according to stratification: publication year, country, inclusion time of patients, patients with prior radiotherapy, age, primaries or recurrent, tumor size, concurrent chemoradiotherapy proportion, dose rate, image modality for planning, and interstitial proportion. Results: A total of 879 patients with vaginal cancer were identified from 18 studies. Among them, 293 cases were primary vaginal cancer, 573 cases were recurrent cancer in the vagina, and 13 cases were unknown. The probit model showed a significant relationship between the HR-CTV (or CTV) D90 versus the 2-year and 3-year local control, P values were 0.013 and 0.014, respectively. The D90 corresponding to probabilities of 90% 2-year local control were 79.0 GyEQD2,10 (95% CI: 75.3–96.6 GyEQD2,10). Conclusions: A significant dependence of 2-year or 3-year local control on HR-CTV (or CTV) D90 was found. Our research findings encourage further validation of the dose-response relationship of radical radiotherapy for vaginal cancer through protocol based multicenter clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. An isolated vaginal metastasis from rectal cancer: a case report.
- Author
-
Sakhri, Saida, Zemni, Ines, Ayadi, Mohamed Ali, Ghazouani, Ayoub, Boujelbene, Nadia, and Ben Dhiab, Tarek
- Subjects
- *
METASTASIS , *COLORECTAL cancer , *ADJUVANT chemotherapy , *ABDOMINOPERINEAL resection , *COMPUTED tomography , *RECTAL cancer - Abstract
Introduction: Vaginal metastasis from colorectal cancer is a rare occurrence, typically associated with other metastatic lesions. Isolated metastasis is exceedingly uncommon, with only a few cases documented in the literature. Vaginal involvement in colorectal cancer primarily results from direct contiguous spread from the primary tumor. Case presentation: We present the case of a 70-year-old African woman diagnosed with adenocarcinoma of the middle rectum. She underwent chemotherapy, radiotherapy, and subsequent anterior resection. After 2 months, an isolated metastasis of rectal cancer was identified in the lower third of the left vaginal wall, confirmed by biopsy. Colonoscopy ruled out colorectal recurrence. Thoraco-abdominal computed tomography scan showed no distant metastases. The patient underwent abdominoperineal resection, removing the lateral and posterior vaginal wall with free macroscopic margins and a definitive colostomy. The final histopathological analysis confirmed the diagnosis of moderately differentiated adenocarcinoma of the vagina, measuring 5 × 4.5 cm. The rectal wall was extrinsically invaded by the tumor down to the muscularis propria while respecting the rectal mucosa. Resection margins were negative. The patient was discharged 1 week postoperation with no complications. Adjuvant chemotherapy was indicated, and the patient is currently tolerating the treatment well. Conclusion: Vaginal metastases from colorectal cancer are extremely rare. A vigilant gynecological examination is recommended during the follow-up of colorectal cancer patients. Diagnosis can be challenging, especially if the metastatic lesion is small and asymptomatic, even after standard radiological examination. Surgical resection followed by chemotherapy is a valid option for patients with early isolated metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Structured Literature Review to Identify Human Papillomavirus's Natural History Parameters for Dynamic Population Models of Vaccine Impacts.
- Author
-
Diakite, Ibrahim, Martins, Bruno, Owusu-Edusei, Kwame, Palmer, Cody, Patterson-Lomba, Oscar, Gomez-Lievano, Andres, Zion, Abigail, Simpson, Ryan, Daniels, Vincent, and Elbasha, Elamin
- Subjects
- *
LITERATURE reviews , *HUMAN papillomavirus , *GENITAL warts , *NATURAL history , *VULVAR cancer , *PENILE cancer , *CERVICAL intraepithelial neoplasia - Abstract
Human papillomavirus (HPV) is a common sexually transmitted virus that can cause cervical cancer and other diseases. Dynamic transmission models (DTMs) have been developed to evaluate the health and economic impacts of HPV vaccination. These models typically include many parameters, such as natural history of the disease, transmission, demographic, behavioral, and screening. To ensure the accuracy of DTM projections, it is important to parameterize them with the best available evidence. This study aimed to identify and synthesize data needed to parametrize DTMs on the natural history of HPV infection and related diseases. Parameters describing data of interest were grouped by their anatomical location (genital warts, recurrent respiratory papillomatosis, and cervical, anal, vaginal, vulvar, head and neck, and penile cancers), and natural history (progression, regression, death, cure, recurrence, detection), and were identified through a systematic literature review (SLR) and complementary targeted literature reviews (TLRs). The extracted data were then synthesized by pooling parameter values across publications, and summarized using the range of values across studies reporting each parameter and the median value from the most relevant study. Data were extracted and synthesized from 223 studies identified in the SLR and TLRs. Parameters frequently reported pertained to cervical cancer outcomes, while data for other anatomical locations were less available. The synthesis of the data provides a large volume of parameter values to inform HPV DTMs, such as annual progression rates from cervical intraepithelial neoplasia (CIN) 1 to CIN 2+ (median of highest quality estimate 0.0836), CIN 2 to CIN 3+ (0.0418), carcinoma in situ (CIS) 2 to local cancer+ (0.0396), and regional to distant cancer (0.0474). Our findings suggest that while there is a large body of evidence on cervical cancer, parameter values featured substantial heterogeneity across studies, and further studies are needed to better parametrize the non-cervical components of HPV DTMs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Vulva-Vajen Tümörlerinde Görüntüleme.
- Author
-
Faraşat, Mustafa and Pekindil, Gökhan
- Subjects
POSITRON emission tomography computed tomography ,POSITRON emission tomography ,MAGNETIC resonance imaging ,VULVAR cancer ,VAGINAL cancer - Abstract
Copyright of Türk Radyoloji Seminerleri is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
36. Long-term outcomes of vulvar or vaginal cancer patients undergoing laparoendoscopic single-site inguinal lymphadenectomy.
- Author
-
Jing-Yun Xu, Tian-Xiang Yu, Xiao-Ming Guan, Bo Ding, Mu-Lan Ren, and Yang Shen
- Subjects
- *
LYMPHADENECTOMY , *VULVAR cancer , *VAGINAL cancer , *CANCER patients , *WOUND infections , *LYMPH nodes - Abstract
Introduction: Laparoendoscopic single-site inguinal lymphadenectomy (LESS-IL), a minimally invasive technique, has been reported in patients with vulvar or vaginal cancer regarding its safety and feasibility. However, the long-term outcomes, especially oncologic outcomes, are still lacking. We aimed to evaluate the long-term outcomes of LESS-IL to confirm its safety further. Patients and Methods: Data were prospectively collected from patients with vulvar or vaginal cancer who underwent LESS-IL at our institution between July 2018 and June 2021. The patients were followed up for at least 12 months. All procedures were performed according to treatment standards. Short- and long-term complications and oncologic outcomes were analysed. Results: A total of 16 patients undergoing 28 LESS-IL procedures were identified, amongst whom 4 underwent unilateral LESS-IL. The median numbers of excised groin lymph nodes were 9.0 (6.5-11.8) and 10.5 (8.3-12.0) in each left and right groin, respectively. Short-term complications occurred in 4 (25%) patients, including 18.7% lymphocele and 6.3% wound infection. Long-term complications regarding lower-limb lymphoedema appeared in 6 (37.5%) patients. Most short- and long-term complications were Clavien-Dindo 1 or 2, accounting for 90% of all post-operative issues. After a median follow-up of 27 (21.3-35.8) months, only 1 (6.3%) patient had isolated inguinal recurrence at 13 months postoperatively. No local or distant recurrence occurred. Conclusion: Our results suggest that LESS-IL is associated with little incidence of complications and promising oncologic outcomes, further demonstrating the safety and feasibility of the LESS-IL technique in patients requiring IL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Laparoscopic pelvic exenteration for malignant tumors of the female reproductive system: a case series
- Author
-
Vladimir K. Lyadov, Andrey S. Nevrov, Marat R. Garipov, Alexey N. Moskalenko, Timofey V. Simbiryov, and Vsevolod N. Galkin
- Subjects
laparoscopy ,pelvic exenteration ,cervical cancer ,endometrial cancer ,ovarian cancer ,vaginal cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background. Surgical treatment of locally advanced and recurrent malignant neoplasms of the female reproductive system is a difficult task requiring extensive multivisceral resections and exenteration. Minimally invasive access allows for less traumatic intervention and improved visualization, potentially leading to improved oncologic outcomes and fewer complications. Aim. To evaluate intraoperative and early postoperative results of laparoscopic pelvic exenterations. Materials and methods. 12 laparoscopic pelvic exenteration were performed between December 2022 and September 2023. Strict selection of patients for laparoscopic access was not performed. Local recurrence was noted in 8 patients, in 3 cases there was continued growth after chemoradiotherapy. 8 patients had a history of pelvic irradiation. 9 women had received drug therapy in the past. Results. Total exenteration was performed in 5 patients, anterior exenteration in 5 patients, and posterior exenteration in 2 patients. The average duration of the operation was 420.8±99.2 (300–625) minutes, the average volume of blood loss was 166.7±98.5 (100–400) ml. Significant postoperative complications (Clavien–Dindo grade III) were registered in two cases: pelvic abscess that required relaparoscopy and sanation, as well as intra-abdominal abscess – drained under ultrasound control. In one case on the 18th day after the surgical intervention a fatal outcome (Clavien–Dindo grade V) due to pulmonary embolism was registered. The median postoperative bed-day was 14.5 (8–32) days. Conclusion. Laparoscopic access for pelvic exenteration improves intraoperative and early postoperative results. It is necessary to further improve the techniques of this intervention and to define clear indications for its performance, which will allow to achieve better treatment results.
- Published
- 2024
- Full Text
- View/download PDF
38. Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- Author
-
National Cancer Institute (NCI) and Lee Shulman, Professor
- Published
- 2023
39. Image-Guided Gynecologic Brachytherapy
- Author
-
National Cancer Institute (NCI)
- Published
- 2023
40. Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments (ORGANOIDES)
- Author
-
CNRS - Pr Chantal PICHON
- Published
- 2023
41. Case report: Synchronous tumors of the female reproductive tract in systemic lupus erythematosus: report of two cases and review of the literature.
- Author
-
Ling Wang, Qin Zhang, Nan Shi, Jiaxi Wang, Shuang Song, Huadi Yang, and Xingbei Chen
- Subjects
GENITALIA ,SYSTEMIC lupus erythematosus ,LITERATURE reviews ,AUTOIMMUNE diseases ,VULVAR cancer ,VAGINAL cancer - Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple systems. Patients with SLE are prone to a variety of malignancies, especially neoplasms of the female reproductive tract. Synchronous tumors, considered to involve multiple sites, are rare in the female reproductive tract. There are hardly any reports of SLE with synchronous reproductive tract tumors. Case presentation: We report the occurrence of two to three reproductive tract tumors in two women with SLE. A 52-year-old woman was diagnosed with vulvar cancer and cervical cancer. Another woman, aged 67, was diagnosed with concurrent vulvar cancer, vaginal cancer, and cervical cancer and also presented with a suspected lung cancer. Conclusion: The presence of synchronous tumors of the reproductive tract in patients with SLE is uncommon and can be easily disregarded. It is crucial to highlight that SLE patients with multiple primary malignancies exhibit notable late-stage presentation at the time of diagnosis, inadequate disease-free survival, poor overall survival, rapid progression rates, and mortality. Consequently, greater awareness must be raised regarding synchronous reproductive tract tumors in patients with SLE. Regular comprehensive cancer screening and management should be implemented for individuals diagnosed with SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Development and clinical implementation of simple needle attachment post placement interstitial template (SNAPP-IT) enabling a shorter, more direct needle path while preserving tumor visualization.
- Author
-
Baniel, Claire C., Hui, Caressa, Franco, Pete A., Niedermayr, Thomas, and Kidd, Elizabeth A.
- Subjects
- *
INTERSTITIAL brachytherapy , *DATA visualization , *NEEDLES & pins , *DATABASES , *VAGINAL cancer , *TUMORS - Abstract
Historical gynecologic interstitial brachytherapy templates block direct tumor visualization during needle placement, presenting an opportunity for clinical innovation to develop a novel interstitial template allowing direct tumor visualization during needle insertion. We designed and implemented a novel interstitial template, simple needle attachment post placement interstitial template (SNAPP-IT), that allowed direct visualization of the target vaginal tumor during interstitial needle placement while maintaining the ability to individually secure needles to the template, allow a vaginal cylinder, suture holes for securing to the perineum, MRI compatibility and sterilizable for repeat use. Procedure outcomes including procedure time, needle path lengths, and plan dosimetry were prospectively captured in a patient database. Forty gynecologic interstitial brachytherapy cases were recorded (20 SNAPP-IT, 20 traditional templates). Needle insertion depth was reduced using the SNAPP-IT in comparison with traditional interstitial templates (11.8 cm vs. 3.6 cm, p < 0.0001). The average CTV volume was 25.6 cc for SNAPP-IT and 20.7 cc for traditional; both methods averaged a similar number of needles (15.8, 15.6). Dosimetric constraints were similarly met in both treatment groups. Procedures performed using the SNAPP-IT were shorter compared with those performed with traditional interstitial devices (83.4 minutes vs. 100.7 minutes) and there were no post-operative infections in the SNAPP-IT group. Implementation of a novel gynecologic interstitial brachytherapy template (SNAPP-IT) reduced procedure times, allowed direct tumor visualization, and decreased needle insertion depth. SNAPP-IT provides a useful alternative approach for vaginal interstitial brachytherapy, may increase brachytherapist efficiency with complex procedures and potentially expands access to interstitial brachytherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review.
- Author
-
Șandru, Florica, Radu, Andreea-Maria, Petca, Aida, Dumitrașcu, Mihai Cristian, Petca, Răzvan-Cosmin, and Roman, Alexandra-Maria
- Subjects
HUMAN papillomavirus vaccines ,SKIN diseases ,GENITAL warts ,VULVAR cancer ,HUMAN papillomavirus ,VAGINAL cancer ,MUCOUS membranes - Abstract
Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.
- Author
-
Kraus, Fabian B. T., Sultova, Elena, Heinrich, Kathrin, Jung, Andreas, Westphalen, C. Benedikt, Tauber, Christina V., Kumbrink, Jörg, Rudelius, Martina, Klauschen, Frederick, Greif, Philipp A., König, Alexander, Chelariu-Raicu, Anca, Czogalla, Bastian, Burges, Alexander, Mahner, Sven, Wuerstlein, Rachel, and Trillsch, Fabian
- Subjects
- *
VULVAR cancer , *VAGINAL cancer , *INDIVIDUALIZED medicine , *HUMAN papillomavirus , *GENETICS , *EUGENICS - Abstract
Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker-guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody–drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Primary vaginal cancer after hysterectomy for benign conditions: a systematic review of the literature.
- Author
-
Jing Qian, Kaoma Gracious, Li Chen, and Song Xu
- Subjects
VAGINAL cancer ,HYSTERECTOMY ,UTERINE hemorrhage ,UTERINE prolapse ,MEDICAL screening ,CANCER patients ,DISEASE risk factors - Abstract
Background: Primary vaginal cancer is a rare condition. Some studies have revealed an increased risk of vaginal cancer among patients who have undergone hysterectomy for premalignant and malignant cervical disease. However, there is limited literature available on primary vaginal cancer following hysterectomy for benign conditions. Objectives: This review aimed to investigate available evidence on clinical characteristics, treatments, and outcomes of primary vaginal cancer following hysterectomy for benign diseases. Additionally, we provide a case of a patient who developed primary vaginal cancer 10 years after undergoing hysterectomy for abnormal uterine bleeding. Search strategy: We conducted a comprehensive literature search on PubMed, Scopus, Web of Science using a combination of title and abstract represented by "hysterectomy", and "vaginal cancer"; "vaginal neoplasm"; and "cancer of vagina". No article type restrictions were applied. Main results: Eight studies with a total of 56 cases were included in this review. The main symptom observed was vaginal bleeding. Squamous cancer was found to be the most common type, followed by adenocarcinoma. The majority of vaginal cancer cases occurred approximately 10 years after undergoing hysterectomy. The most common location of the tumor was in the vaginal apex. The management approaches varied and details were available in 25 cases. Among these, 7 cases were treated with radiotherapy alone, 1 case received concurrent chemoradiation therapy, and the of rest of the cases underwent surgery as the primary treatment, with or without additional adjuvant therapy. Data of follow-up was available for 15 cases, with 2 cases resulting in death and 2 cases experiencing recurrence. The other cases were alive and well at the time of considered follow up. Conclusion: Primary vaginal cancer after hysterectomy for benign conditions is an extremely rare condition. It is essential to have high-level evidence to guide the screening and treatment strategy for this rare condition. A part of women who have undergone hysterectomy for benign disorders can benefit from vaginal cytology evaluation. It is reasonable to postpone the initial screening after surgery and to extend the interval between subsequent screenings. Further retrospective case-control trials are expected to determine which specific subgroups of patients mentioned above might most potentially benefit from screening. The treatment decision for vaginal cancer after hysterectomy is more favorable to radiotherapy-based management rather than surgery. Vaginal endometrioid adenocarcinoma may arise from the malignant transformation of endometriosis. More studies are expected to investigate the correlation between these two diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Place of radiotherapy for treatment of metastatic cervical, vaginal and endometrial uterine cancer.
- Author
-
Escande, A., Leblanc, J., Hannoun-Levi, J.-M., Renard, S., Ducassou, A., Hennequin, C., and Chargari, C.
- Subjects
- *
UTERINE cancer , *RADIOTHERAPY , *DISEASE progression , *RADIOISOTOPE brachytherapy , *ENDOMETRIAL cancer - Abstract
Beyond classical palliative-intent irradiation schemes, there are increasing data suggesting a benefit for intensive locoregional treatments in metastatic gynecological cancers. Such approach aims at avoiding local symptoms related to tumor progression, but may also improve survival outcome by shrinking tumor burden to a microscopic state. This strategy is rarely considered upfront (in highly selected patients with very limited oligometastatic disease), but rather after systemic treatment. In case of tumor response (especially if complete response) of the metastatic sites, pelvic ± para-aortic radiotherapy can be considered in combination with a brachytherapy boost to obtain long-term local control, in particular in cervical or vaginal cancer patients. Such approach seems particularly relevant when there is isolated persistence or progression of macroscopic disease within the pelvis. In parallel, there is also an increasing place for radiotherapy of oligo-metastatic sites. We review the literature on the place of radiotherapy in the management of cancers of the cervix and metastatic endometrial cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Predictive factors of surgical complications after pelvic exenteration for gynecological malignancies: a large single-institution experience.
- Author
-
Tortorella, Lucia, Marco, Cintoni, Loverro, Matteo, Carmine, Conte, Persichetti, Eleonora, Bizzarri, Nicolò, Barbara, Costantini, Francesco, Santullo, Foschi, Nazario, Gallotta, Valerio, Avesani, Giacomo, Chiantera, Vito, Ercoli, Alfredo, Fanfani, Francesco, Fagotti, Anna, Mele, Maria Cristina, Restaino, Stefano, Alletti, Salvatore Gueli, Scambia, Giovanni, and Vizzielli, Giuseppe
- Subjects
- *
PELVIC exenteration , *SURGICAL complications , *VAGINAL cancer , *URINARY diversion , *ODDS ratio , *GYNECOLOGIC care , *PELVIC examination - Abstract
Objective: To evaluate pre-operative predictors of early (<30 days) severe complications (grade Dindo 3+) in patients with gynecological malignancy submitted to pelvic exenteration (PE). Methods: We retrospectively analyzed 129 patients submitted to surgery at Fondazione Policlinico Gemelli between 2010 and 2019. We included patients affected by primary or recurrent/persistent cervical, endometrial, or vulvar/vaginal cancers. Post-operative complications were graded according to the Dindo classification. Logistic regression was used to analyze potential predictors of complications. Results: We performed 63 anterior PE, 10 posterior PE, and 56 total PE. The incidence of early severe post-operative complications was 27.9% (n=36), and the early mortality rate was 2.3% (n=3). More frequent complications were related to the urinary diversion and intestinal surgery. In univariable analysis, hemoglobin ≤10 g/dL (odds ratio [OR]=4.2; 95% confidence interval [CI]=1.65-10.7; p=0.003), low albumin levels (OR=3.9; 95% CI=1.27-12.11; p=0.025), diabetes (OR=4.15; 95% CI=1.22-14.1; p=0.022), 2+ comorbidities at presentation (OR=5.18; 95% CI=1.49-17.93; p=0.012) were predictors of early severe complications. In multivariable analysis, only low hemoglobin and comorbidities at presentation were independent predictors of complications. Conclusion: Pelvic exenteration is an aggressive surgery characterized by a high rate of postoperative complications. Pre-operative assessment of comorbidities and patient health status are crucial to better select the right candidate for this type of surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Clinical Features of Li-Fraumeni Syndrome in Korea.
- Author
-
Ran Song, Sun-Young Kong, Wonyoung Choi, Eun-Gyeong Lee, Jaeyeon Woo, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, and So-Youn Jung
- Subjects
- *
LI-Fraumeni syndrome , *THYROID cancer , *SKIN cancer , *NONSENSE mutation , *CANCER relapse , *GENETIC testing , *VAGINAL cancer , *CA 19-9 test - Abstract
Purpose Li-Fraumeni syndrome (LFS) is a hereditary disorder caused by germline mutation in TP53. Owing to the rarity of LFS, data on its clinical features are limited. This study aimed to evaluate the clinical characteristics and prognosis of Korean patients with LFS. Materials and Methods Patients who underwent genetic counseling and confirmed with germline TP53 mutation in the National Cancer Center in Korea between 2011 and 2022 were retrospectively reviewed. Data on family history with pedigree, types of mutation, clinical features, and prognosis were collected. Results Fourteen patients with LFS were included in this study. The median age at diagnosis of the first tumor was 32 years. Missense and nonsense mutations were observed in 13 and one patients, respectively. The repeated mutations were p.Arg273His, p.Ala138Val, and pPro190Leu. The sister with breast cancer harbored the same mutation of p.Ala138Val. Seven patients had multiple primary cancers. Breast cancer was most frequently observed, and other types of tumor included sarcoma, thyroid cancer, pancreatic cancer, brain tumor, adrenocortical carcinoma, ovarian cancer, endometrial cancer, colon cancer, vaginal cancer, skin cancer, and leukemia. The median follow-up period was 51.5 months. Two and four patients showed local recurrence and distant metastasis, respectively. Two patients died of leukemia and pancreatic cancer 3 and 23 months after diagnosis, respectively. Conclusion This study provides information on different characteristics of patients with LFS, including types of mutation, types of cancer, and prognostic outcomes. For more appropriate management of these patients, proper genetic screening and multidisciplinary discussion are required. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Vaginal Cancer: Association with Long Term Use of Pessary in Pelvic Organ Prolapse, a Case Series.
- Author
-
BEGUM, H., RASHID, M., SHAMIMA, H., and ZOHRA, F.
- Subjects
- *
PELVIC organ prolapse , *VAGINAL cancer , *GYNECOLOGIC cancer , *VAGINAL discharge , *PELVIC pain , *UTERINE hemorrhage , *REFUGEE camps - Abstract
Vaginal cancer, rarest form of gynaecological cancer (0.6%) has been found to be associated with long term use of vaginal ring pessary, which have long been used in alternative management of pelvic organ prolapse (POP) other than surgery. A survey was done in remote areas of Cox's bazar, refugee camp in 2019 where out of 52 cases of pelvic organ prolapse, 7 cases found to use vaginal ring pessary for long and out of 7, vaginal cancer developed in 4 cases. All of them were aged women above 60 and had defaulted follow up presented with vaginal bleeding, varying discharge and pain of varying intensity. One patient had only local lesion -surgical removal followed by radiotherapy and 2nd one, 68 years, received neo-adjuvant therapy and died before planned surgery. The 3rd one, aged 79, did not come for follow up once diagnosis vaginal cancer done and advised for definitive surgical treatment, family refused operation and she passed away after 2 years at 81 years. The 4th one declined further investigations and any form of treatment when diagnosed with vaginal cancer. So, all patients of pelvic organ prolapse should be informed thoroughly (both verbal and written informed consent) before inserting pessary for potential long term serious consequences where strict compliance must be ensured for subsequent regular follow up and biopsy should be mandatory for any suspicious chronic vaginal ulcers among them. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature.
- Author
-
Vitale, Maria Giuseppa, Nasso, Cecilia, Riccò, Beatrice, Bocconi, Alessandro, Chiavelli, Chiara, Baldessari, Cinzia, Pipitone, Stefania, Bacchelli, Francesca, Botticelli, Laura, Dominici, Massimo, and Sabbatini, Roberto
- Subjects
- *
LITERATURE reviews , *VAGINAL cancer , *PEMBROLIZUMAB , *CARCINOMA , *GOVERNMENT aid , *VULVAR cancer , *GYNECOLOGIC cancer - Abstract
Introduction: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, and vaginal carcinomas notoriously develop resistance to treatment, and consequently, their prognosis is still poor. Case Presentation: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy. Conclusion: Pembrolizumab might represent a promising option for the management of vaginal and vulvar cancer, but data to support its use in this setting are still lacking. This case highlights the need for further investigation and trial designs for this rare disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.